Novo Nordisk's phase 3 data for hemophilia hopeful fail to shake off Pfizer's shadow

Novo Nordisk insists its rival to Roche's Hemlibra will make a “good offering” for hemophilia patients even though mixed phase 3 data suggest that Pfizer’s own candidate could have an edge in the race to market.